Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Applying to George Washington University Cancer Center · Washington D.C., District of Columbia
Answer a few short questions to share with the research team.